AR080322A1 - AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHOD - Google Patents
AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHODInfo
- Publication number
- AR080322A1 AR080322A1 ARP110100596A AR080322A1 AR 080322 A1 AR080322 A1 AR 080322A1 AR P110100596 A ARP110100596 A AR P110100596A AR 080322 A1 AR080322 A1 AR 080322A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- entacapone
- carbidopa
- pharmaceutical composition
- oral dose
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004205 carbidopa Drugs 0.000 title abstract 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title abstract 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title abstract 2
- 229960003337 entacapone Drugs 0.000 title abstract 2
- 229960004502 levodopa Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000013265 extended release Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona una unidad de composicion farmacéutica de dosis oral que comprende un levodopa de a) o las sales de eso alrededor de 50 mg alrededor a 300 mg en forma de liberacion prolongada, carbidopa de b) o las sales de eso alrededor de 10 mg al magnesio cerca de 100 en liberacion extendida y entacapone de c) o las sales de eso alrededor de 100 mg alrededor a 1000 mg en forma inmediata de liberacion, opcionalmente de otros excipientes farmacéutico aceptables. Se relaciona con el proceso de la preparacion de tales composiciones.An oral dose pharmaceutical composition unit is provided comprising a levodopa of a) or salts thereof about 50 mg about 300 mg in the form of prolonged release, carbidopa of b) or salts thereof about 10 mg at about 100 mg in extended release and entacapone of c) or salts thereof about 100 mg to about 1000 mg immediately immediately, optionally other pharmaceutically acceptable excipients. It relates to the process of preparing such compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110100596 AR080322A1 (en) | 2011-02-25 | 2011-02-25 | AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHOD |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110100596 AR080322A1 (en) | 2011-02-25 | 2011-02-25 | AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHOD |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080322A1 true AR080322A1 (en) | 2012-03-28 |
Family
ID=46003372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100596 AR080322A1 (en) | 2011-02-25 | 2011-02-25 | AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHOD |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR080322A1 (en) |
-
2011
- 2011-02-25 AR ARP110100596 patent/AR080322A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001874A1 (en) | Solid oral modified release dosage form comprising pridopidine and a speed control excipient; pharmaceutical formulation comprising the dosage form; use of the dosage form or pharmaceutical formulation to treat a neurodegenerative or dopamine-related disease, such as huntington's disease, among others. | |
| UY33479A (en) | THERAPEUTIC COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, TREATMENT METHOD AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| UY37998A (en) | ANTIVIRAL AGENTS AGAINST HEPATITIS B | |
| MX2020012310A (en) | Sustained-release formulations of colchicine and methods of using same. | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| PE20170302A1 (en) | USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE | |
| MX2016010179A (en) | COMPOSITIONS OF DONEPEZILO AND METHODS TO TREAT ALZHEIMER'S DISEASE. | |
| UY33480A (en) | THERAPEUTIC COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, TREATMENT METHOD AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
| MX351584B (en) | Aqueous pharmaceutical formulation of tapentadol for oral administration. | |
| UY33183A (en) | INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| AR080491A1 (en) | ORAL FORMULATIONS AND LIPOFILIC SALTS OF METHYLNTREXONE | |
| AR069508A1 (en) | DERIVATIVES OF QUINOLINA 057; A PROCESS FOR PREPARATION; A PHARMACEUTICAL COMPOSITION; THE PREPARATION OF THIS AND THE USE OF THE COMPOUND TO PREPARE A MEDICINAL PRODUCT | |
| PE20150161A1 (en) | USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| TN2015000135A1 (en) | Modified release formulations for oprozomib | |
| UA102111C2 (en) | Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof | |
| MX2013001279A (en) | Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form. | |
| ECSP16005208A (en) | STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS | |
| GR1008228B (en) | Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof | |
| DOP2013000115A (en) | FORMULATION OF A COMPLEX THAT INCLUDES LERCANIDIPINE AND VALSARTAN CHLORHYDRATE AND METHOD FOR THE PREPARATION OF THE SAME | |
| IN2014DN09240A (en) | ||
| AR080322A1 (en) | AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHOD | |
| PE20160245A1 (en) | STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A DISPERSABLE TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| IN2013MU03428A (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |